Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)

• Status: Completed
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to find out if AZD2423 can reduce inflammation in the lungs of patients with mild COPD.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca

Criteria

Inclusion Criteria:

• Only women of non-child bearing potential are included in the study i.e. women who are permanently or surgically sterilised or post menopausal.

• ≥ 40 years of age at Visit 1

• Clinical diagnosis of COPD (GOLD stage 1)

• FEV1 ≥ 80% of the predicted normal post-bronchodilator at Visit 1 (GOLD stage 1)

• FEV1/FVC <70% post-bronchodilator at Visit 1 (GOLD stage 1)

Exclusion Criteria:

• Any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk or influence the way the drug works

• Any clinically relevant abnormal findings in physical examination, blood or urine test results, vital signs or ECG at Visit 1 that may put the subject at risk during the study, affect their ability or take part or influence the results of the study

• A past history or current indication of renal (kidney) failure

• Subjects at risk of active tuberculosis or of disease reactivation

• Subjects who have had any clinically significant illness within 4 weeks before Visit 2 (start of treatment)